BiotechTube

Rituximab + 375 mg/m2 RRituximab

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematological Malignancies

Conditions

Hematological Malignancies

Trial Timeline

Sep 1, 2006 → Aug 1, 2012

NCT ID
NCT00379587

About Rituximab + 375 mg/m2 RRituximab

Rituximab + 375 mg/m2 RRituximab is a phase 1/2 stage product being developed by Biogen for Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00379587. Target conditions include Hematological Malignancies.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT00379587Phase 1/2Completed

Competing Products

20 competing products in Hematological Malignancies

See all competitors
ProductCompanyStageHype Score
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
NemtabrutinibMerckPhase 1
33
Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher doseNovartisPhase 1
33
LBH589NovartisPhase 1
33
HDM201 + ancillary treatmentNovartisPhase 1
33
Ibandronate + Vitamin SupplementsRochePhase 3
77
Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer)AmgenPhase 2/3
64
Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363Gilead SciencesPre-clinical
22
Magrolimab + AzacitidineGilead SciencesPhase 1
32
piperacillin-tazobactam + glycopeptidePfizerPre-clinical
22
Isatuximab SAR650984 + Dexamethasone + DexamethasoneSanofiPhase 1/2
40
Thymoglobulin Injectable ProductSanofiPhase 2
51
ATG + Post-transplantation cyclophosphamideSanofiPre-clinical
22
Mycophenolate Mofetil (MMF) + Thymoglobulin + SirolimusSanofiPhase 2
51
HMPL-506HUTCHMEDPhase 1
28

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82